#USA #San Francisco #Biomanufacturing #Stämm #Bioprocessor

Stämm Takes a Step Forward in Biomanufacturing

Stämm has recently unveiled its latest innovation, the High-Throughput Bioprocessor (HTB), marking a significant advancement in the field of biomanufacturing. This automated, single-use platform is designed for both adherent and suspension cell cultures, setting new standards in efficiency and accessibility.

One of the standout features of the HTB is its ability to eliminate hydrodynamic shear stress, a common issue in traditional biomanufacturing methods, which can adversely affect sensitive cell populations. The system utilizes a Bubble-Free Bioreactor (BFB), a unique 3D-printed consumable that shifts away from the conventional impeller design. Instead of using bubbling or sparging, the HTB relies on laminar flow, mimicking natural capillary networks found in living tissues. This innovative approach ensures effective nutrient transport and gas exchange without causing turbulence that would disrupt cell viability.

CEO of Stämm, Yuyo Llamazares, emphasizes the importance of this technology not only in terms of efficiency but also accessibility. He mentions, "Biomanufacturing has been constrained by equipment designed for a centralized, high-volume world that no longer reflects where medicine is going. Our vision in creating the HTB is that no patient in Alaska, São Paulo, or Nairobi should have to wait for therapy due to the limitations of centralized infrastructure."

The HTB is built to confront the challenges faced by the global cell and gene therapy manufacturing market. Traditionally, production has been overly centralized and capital-intensive, catering poorly to the personalized nature of modern therapies. The modular and plug-and-play design of the HTB addresses these bottlenecks effectively. By eliminating the need for large stainless-steel vessels and instead employing snap-in cartridges, the new platform is set to streamline development timelines and reduce manufacturing costs significantly.

As research and development processes in biomanufacturing become increasingly complex, the HTB looks to provide a solution that adapts to these demands. The bioprocessor not only caters to current needs but also has the potential to evolve in response to future innovations in biologics and cell gene therapies. Stämm aims to facilitate easier and faster access to advanced treatments worldwide, ensuring that state-of-the-art therapies are not limited by geographical constraints.

Currently available for process development within Research Use Only (RUO) applications, the HTB stands ready to assist pharma and biotech teams exploring pre-clinical production avenues, including CAR-T therapies, stem cell expansions, and monoclonal antibody workflows. Stämm encourages interested parties to reach out via their official website for further collaboration opportunities.

In summary, Stämm's introduction of the High-Throughput Bioprocessor signals a major shift in the biomanufacturing landscape. It offers a promising pathway toward decentralized production and aims to make advanced therapies accessible to every corner of the globe. With a commitment to innovation and efficiency, Stämm is poised to transform the future of biomanufacturing, breaking down barriers that have traditionally hindered patient access to life-saving therapies.